Report of Foreign Issuer (6-k)
May 21 2019 - 8:34AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
TO RULE 13a-16 or 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2019
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name into
English)
4
th
Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form
20-F
x
Form 40-F
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
¨
Mereo BioPharma Group plc
("Mereo" or the "Company"
or the "Group")
Notice of AGM
London, May 20, 2019
- Mereo BioPharma
Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, today announces
that its Annual General Meeting is to be held on June 19, 2019 at 3:00 p.m. (London time) at the Marlborough Theatre, The King's
Fund, 11-13 Cavendish Square, London W1G 0AN, United Kingdom.
A copy of the Notice of Annual General
Meeting is available on the Company's website:
www.mereobiopharma.com
.
About Mereo
Mereo is a biopharmaceutical company focused on the development
and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare diseases. Mereo's strategy
is to selectively acquire product candidates that have substantial preclinical, clinical and manufacturing data packages. Mereo's
four product candidates have previously generated positive clinical data for Mereo's target indications or in related indications.
Mereo has commenced randomized Phase 2 clinical trials for all four of the product candidates. In connection with the merger
with OncoMed, Mereo added two candidates to its pipeline, Navicixizumab and Etigilimab.
|
·
|
BPS-804 for osteogenesis imperfecta (OI).
In October 2018, the Company announced completion of enrollment of 112 adult patients in a Phase 2b dose ranging study with
initial data expected in Q2 2019 and top-line dose ranging data in late 2019. A pediatric Phase 3 study design has also been approved
by the EMA. BPS-804 has orphan designation in the U.S. and the EU and has been accepted into the PRIME and Adaptive Pathways in
EU;
|
|
·
|
MPH-966 for alpha-1 antitrypsin deficiency
(AATD). The Company recently announced dosing of the first patient in a Phase 2 dose ranging study in the U.S. with data expected
around the end of 2019;
|
|
·
|
BCT-197 for severe exacerbations of COPD. The
Company announced positive Phase 2 data in May 2018 and recently announced the outline of the pivotal Phase 3 study including the
primary and key secondary endpoints following the successful end of Phase 2 Type B meeting with the FDA;
|
|
·
|
BGS-649 for hypogonadotropic hypogonadism
(HH). The Company announced positive top-line Phase 2b data in March 2018 and positive results from the Phase 2b safety extension
study in December 2018;
|
|
·
|
Navicixizumab has completed a Phase 1a
single-agent clinical trial in patients with advanced solid tumors and is currently in a Phase 1b trial in combination with a standard
paclitaxel regimen in patients with platinum-resistant ovarian cancer. This study recently completed enrolment; and
|
|
·
|
Etigilimab has completed a single-agent
Phase 1a trial in patients with advanced or metastatic solid tumors and is currently in a Phase 1b combination study with nivolumab.
Etigilimab is part of OncoMed's prior collaboration with Celgene. Celgene has the option to obtain an exclusive licence to develop
and commercialize the product. If Celgene exercises such option, OncoMed (now a wholly-owned indirect subsidiary of Mereo)
will be eligible to receive a $35 million opt in payment.
|
Further Enquiries
Mereo
|
+44 (0)333 023 7300
|
Denise Scots-Knight, Chief Executive Officer
|
|
Richard Jones, Chief Financial Officer
|
|
|
|
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to
Mereo)
|
+44 (0)20 7894 7000
|
Phil Davies
|
|
Will Goode
|
|
|
|
RBC Capital Markets (Joint Broker to
Mereo)
|
+44 (0)20 7653 4000
|
Rupert Walford
Jamil Miah
|
|
|
|
FTI Consulting (Public Relations Adviser to
Mereo)
|
+44 (0)20 3727 1000
|
Simon Conway
|
|
Brett Pollard
|
|
|
|
Burns McClellan (US Public Relations Adviser to Mereo)
|
+01 (0) 212 213 0006
|
Lisa Burns
|
|
Jill Steier
|
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: May 21, 2019
|
MEREO BIOPHARMA GROUP PLC
|
|
|
|
|
|
|
|
|
By:
|
/s/ Charles Sermon
|
|
|
|
Name:
|
Charles Sermon
|
|
|
|
Title:
|
General Counsel
|
|
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Mereo BioPharma (NASDAQ:MREO)
Historical Stock Chart
From Sep 2023 to Sep 2024